A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic syndrome
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Essential hypertension; Metabolic syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual end date (June 2007) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Actual patient number is 45 and location (Germany) added as reported by ClinicalTrials.gov.
- 06 Jul 2007 Status changed from recruiting to completed.